an opioid analgesic is appropriate

June 2011

   Sutent Treatment of unresectable pancreatic neuroendocrine tumor May 2011

 (a) In early 2011, we acquired King, which has an exclusive license from Acura Pharmaceuticals, Inc. (Acura) to sell Oxecta in the U.S., Canada and Mexico.

 Pending U.S. new drug applications (NDA) and supplemental filings:

  PRODUCT INDICATION DATE FILED*

   Tafamidis meglumine Treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) February 2012

   Lyrica Treatment of central neuropathic pain due to spinal cord injury February 2012

   Revatio Pediatric PAH January 2012

   Bosutinib Treatment of previously treated chronic myelogenous leukemia January 2012

   Tofacitinib Treatment of moderate-to-severe active rheumatoid arthritis December 2011

   Apixaban(a) Prevention of stroke and systemic embolism in patients with atrial fibrillation November 2011

   Taliglucerase alfa(b) Treatment of Gaucher disease April 2010

   Genotropin(c) Replacement of human growth hormone deficiency (Mark VII multidose disposable December 2009 device)

   Celebrex(d) Chronic pain October 2009

   Geodon(e) Treatment of bipolar disorder––pediatric filing December 2008

   Remoxy(f) Management of moderate-to-severe pain when a continuous, around-the-clock August 2008 opioid analgesic is needed for an extended period of time

   Spiriva(g) Respimat device for chronic obstructive pulmonary disease January 2008

   Zmax(h) Treatment of bacterial infections––sustained release––acute otitis media (AOM) January 2007 and sinusitis––pediatric filing

   Viviant(i) Osteoporosis treatment and prevention August 2006

   Vfend(j) Treatment of fungal infections––pediatric filing August 2005

 * The dates set forth in this column are the dates on which the FDA accepted our submissions.

(a) This indication for apixaban is being developed in collaboration with our alliance partner, BMS.

(b) In November 2009, we entered into a license and supply agreement with Protalix BioTherapeutics (Protalix), which provides us exclusive worldwide rights, except in Israel, to develop and commercialize taliglucerase alfa for the treatment of Gaucher disease. In April 2010, Protalix completed a rolling NDA with the FDA for taliglucerase alfa. Taliglucerase alfa was granted orphan drug designation in the U.S. in September 2009. In February 2011, Protalix received a “complete response” letter from the FDA for the taliglucerase alfa NDA that set forth additional requirements for approval. On August 1, 2011, Protalix announced that it had submitted its response to the FDA letter.

(c) In April 2010, we received a “complete response” letter from the FDA for the Genotropin Mark VII multidose disposable device submission. In August 2010, we submitted our response to address the requests and recommendations included in the FDA letter. In April 2011, we received a second “complete response” letter from the FDA, requesting additional information. We are assessing the requests and recommendations included in the FDA’s letter.

(d) In June 2010, we received a “complete response” letter from the FDA for the Celebrex chronic pain supplemental NDA. The supplemental